Novel process for the preparation of phenylcarbamates
AssigneeApotex Pharmachem Inc.
InventorsMohammed Abdul Raheem, Zhi-Xian Wang, Eckardt C.G. Wolf
Life of this patent
Estimating the term…
Loading patent…
AssigneeApotex Pharmachem Inc.
InventorsMohammed Abdul Raheem, Zhi-Xian Wang, Eckardt C.G. Wolf
Estimating the term…
This invention relates to a process for the preparation of an aminoalkyl phenyl carbamate compound of formula 1, wherein R1 and R2 independently are hydrogen or C1-6 alkyl; R3 and R4 are the same or different and each is a lower alkyl; or R3 and R4 together with the nitrogen to which they are attached form a cyclic moiety of a three to eight-member ring, with or without a hetero atom like nitrogen or oxygen; R5 and R6 independently are hydrogen, linear, branched or cyclic C1-6 alkyl, allyl, propargyl or benzyl; or R5 and R6 together with the nitrogen to which they are attached form a cyclic moiety of three to eight member ring, with or without a hetero atom like nitrogen or oxygen; the carbon center marked with “*” is racemic or enantiomerically enriched (R)- or (S)-configuration; and pharmaceutically acceptable addition salts, and crystalline and amorphous forms thereof comprising the steps of: i) converting an amine R5R6NH to a carbamoylimidazolium salt of formula 3 wherein R5 and R6 are as defined above; X− is a counterion and R7 is an alkyl or aryl group; ii) reacting in a solvent at a controlled reaction temperature the compound of formula 3 with a compound of formula 4, wherein R1, R2, R3, R4 and “*” are as defined above to give the compound of formula 1; and iii) isolating the compound of formula 1.
A process for the preparation of an aminoalkyl phenyl carbamate compound of formula 1,
A process for the preparation of racemic and enantiomerically enriched forms of ethylmethylcarbamic acid 3-[1-(dimethylamino)ethyl]phenyl ester of formula 6
A process for the preparation of an amorphous form of (S)—N-ethyl-N-methyl-3-[1-(dimethylamino)ethyl]phenyl carbamate-(2R,3R) hydrogen-tartrate salt comprising the steps of stirring a solution of (S)—N-ethyl-N-methyl-3-[1-(dimethylamino)ethyl]phenyl carbamate-(2R,3R) hydrogen-tartrate in water for 0.5-1 hour at 20-25° C., evaporating the water at 45-60° C. under vacuum to give a white solid, and drying the white solid at 40-45° C. for 10-12 hours under vacuum.
The amorphous form of (S)—N-ethyl-N-methyl-3-[1-(dimethylamino)ethyl]phenyl carbamate-(2R,3R) hydrogen-tartrate salt.
The compound of formula 7 wherein X− is a counterion selected from the group consisting of I−, Br−, Cl−, F−, (MeO)SO3−, SO42−, BF4− and OTf−;
N-ethyl-N-methyl-1H-imidazole-1-carboxamide.
1-{[N-ethyl-(N-methyl)amino]carbonyl}-3-methyl-1H-imidazolium iodide.
1-{[N-ethyl-(N-methyl)amino]carbonyl}-3-methyl-1H-imidazolium methyl sulfate.
Dependencies are inferred from the claim text.